PANK1 and pantothenate kinase-associated neurodegeneration: A low molecular weight compound, PZ-2891, that acts as an allosteric Pank activator and modulates CoA levels in vivo was recently developed, and has been explored as a therapeutic modality for pantothenate kinase associated neurodegeneration (PKAN), which is the most common form of NBIA [44].